Palbociclib blocks neutrophilic PI3K activity to alleviate psoriasiform dermatitis.

This is the first study to demonstrate that palbociclib could potentially be used to treat neutrophil-associated psoriasiform dermatitis through the targeting of neutrophilic PI3K activity. Our findings prompt further research to explore the potential of palbociclib and PI3K in psoriasis and other inflammatory diseases.